![Alcide Barberis](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Alcide Barberis
Direktor/Vorstandsmitglied bei EffRx Pharmaceuticals SA
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Lorenzo Bosisio | M | - |
EffRx Pharmaceuticals SA
![]() EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | 12 Jahre |
Jonas Göran Ekblom | M | 59 |
EffRx Pharmaceuticals SA
![]() EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | 8 Jahre |
Göran Harald Linder | M | 62 |
EffRx Pharmaceuticals SA
![]() EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Roberto Maj | M | - |
Telormedix SA
![]() Telormedix SA Pharmaceuticals: MajorHealth Technology Telormedix SA operates as a biopharmaceutical company, that focuses on targeted immunity in the treatment of cancer and other diseases. Its products include TMX-101 for the treatment of localized bladder cancer, TMX-201 for the topical treatment of bladder cancer, skin cancer, and other indications, as well as for use as a vaccine adjuvant, and TMX-302 for use in preclinical trials for the treatment of autoimmune disease. The company was founded in October 2007 by Lorenzo Leoni, Roberto Maj, Rolf M. Zinkernagel and Dennis A. Carson and is headquartered in Lugano, Switzerland. | - |
Arnd Kaltofen-Ehmann | M | 64 |
Oncalis AG
![]() Oncalis AG Pharmaceuticals: MajorHealth Technology Oncalis AG ('Oncology alliances') has been founded in June 2006 as a spin-off from ESBATech AG, a Swiss biotechnology company that has developed technology platforms in both the antibody and small molecule areas of pharmaceutical research. Oncalis has acquired from the mother company all small molecule-related assets, including a yeast-cell based, high- throughput screening platform for receptor tyrosine kinases (RTKs), and a number of specific and potent kinase inhibitors. The company is currently financed by ESBATech's Series A investors, including Novartis Venture Fund, BioMedInvest and Venture Incubator (VI) Partners. Oncalis will now focus on the discovery and development of small molecule inhibitors for oncology indications. | - |
Stuart Holden | M | 82 |
Telormedix SA
![]() Telormedix SA Pharmaceuticals: MajorHealth Technology Telormedix SA operates as a biopharmaceutical company, that focuses on targeted immunity in the treatment of cancer and other diseases. Its products include TMX-101 for the treatment of localized bladder cancer, TMX-201 for the topical treatment of bladder cancer, skin cancer, and other indications, as well as for use as a vaccine adjuvant, and TMX-302 for use in preclinical trials for the treatment of autoimmune disease. The company was founded in October 2007 by Lorenzo Leoni, Roberto Maj, Rolf M. Zinkernagel and Dennis A. Carson and is headquartered in Lugano, Switzerland. | 9 Jahre |
Anders Paul Wiklund | M | 84 |
EffRx Pharmaceuticals SA
![]() EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | - |
Rolf M. Zinkernagel | M | 80 |
Telormedix SA
![]() Telormedix SA Pharmaceuticals: MajorHealth Technology Telormedix SA operates as a biopharmaceutical company, that focuses on targeted immunity in the treatment of cancer and other diseases. Its products include TMX-101 for the treatment of localized bladder cancer, TMX-201 for the topical treatment of bladder cancer, skin cancer, and other indications, as well as for use as a vaccine adjuvant, and TMX-302 for use in preclinical trials for the treatment of autoimmune disease. The company was founded in October 2007 by Lorenzo Leoni, Roberto Maj, Rolf M. Zinkernagel and Dennis A. Carson and is headquartered in Lugano, Switzerland. | - |
Dennis A. Carson | M | 77 |
Telormedix SA
![]() Telormedix SA Pharmaceuticals: MajorHealth Technology Telormedix SA operates as a biopharmaceutical company, that focuses on targeted immunity in the treatment of cancer and other diseases. Its products include TMX-101 for the treatment of localized bladder cancer, TMX-201 for the topical treatment of bladder cancer, skin cancer, and other indications, as well as for use as a vaccine adjuvant, and TMX-302 for use in preclinical trials for the treatment of autoimmune disease. The company was founded in October 2007 by Lorenzo Leoni, Roberto Maj, Rolf M. Zinkernagel and Dennis A. Carson and is headquartered in Lugano, Switzerland. | - |
Adrian Escher | M | - |
Oncalis AG
![]() Oncalis AG Pharmaceuticals: MajorHealth Technology Oncalis AG ('Oncology alliances') has been founded in June 2006 as a spin-off from ESBATech AG, a Swiss biotechnology company that has developed technology platforms in both the antibody and small molecule areas of pharmaceutical research. Oncalis has acquired from the mother company all small molecule-related assets, including a yeast-cell based, high- throughput screening platform for receptor tyrosine kinases (RTKs), and a number of specific and potent kinase inhibitors. The company is currently financed by ESBATech's Series A investors, including Novartis Venture Fund, BioMedInvest and Venture Incubator (VI) Partners. Oncalis will now focus on the discovery and development of small molecule inhibitors for oncology indications. | - |
Peter Traxler | M | - |
Oncalis AG
![]() Oncalis AG Pharmaceuticals: MajorHealth Technology Oncalis AG ('Oncology alliances') has been founded in June 2006 as a spin-off from ESBATech AG, a Swiss biotechnology company that has developed technology platforms in both the antibody and small molecule areas of pharmaceutical research. Oncalis has acquired from the mother company all small molecule-related assets, including a yeast-cell based, high- throughput screening platform for receptor tyrosine kinases (RTKs), and a number of specific and potent kinase inhibitors. The company is currently financed by ESBATech's Series A investors, including Novartis Venture Fund, BioMedInvest and Venture Incubator (VI) Partners. Oncalis will now focus on the discovery and development of small molecule inhibitors for oncology indications. | 5 Jahre |
Hans-Georg Capraro | M | - |
Oncalis AG
![]() Oncalis AG Pharmaceuticals: MajorHealth Technology Oncalis AG ('Oncology alliances') has been founded in June 2006 as a spin-off from ESBATech AG, a Swiss biotechnology company that has developed technology platforms in both the antibody and small molecule areas of pharmaceutical research. Oncalis has acquired from the mother company all small molecule-related assets, including a yeast-cell based, high- throughput screening platform for receptor tyrosine kinases (RTKs), and a number of specific and potent kinase inhibitors. The company is currently financed by ESBATech's Series A investors, including Novartis Venture Fund, BioMedInvest and Venture Incubator (VI) Partners. Oncalis will now focus on the discovery and development of small molecule inhibitors for oncology indications. | 4 Jahre |
Raffaella Pozzi | M | - |
Telormedix SA
![]() Telormedix SA Pharmaceuticals: MajorHealth Technology Telormedix SA operates as a biopharmaceutical company, that focuses on targeted immunity in the treatment of cancer and other diseases. Its products include TMX-101 for the treatment of localized bladder cancer, TMX-201 for the topical treatment of bladder cancer, skin cancer, and other indications, as well as for use as a vaccine adjuvant, and TMX-302 for use in preclinical trials for the treatment of autoimmune disease. The company was founded in October 2007 by Lorenzo Leoni, Roberto Maj, Rolf M. Zinkernagel and Dennis A. Carson and is headquartered in Lugano, Switzerland. | - |
Phillipe Lutz | M | - |
Telormedix SA
![]() Telormedix SA Pharmaceuticals: MajorHealth Technology Telormedix SA operates as a biopharmaceutical company, that focuses on targeted immunity in the treatment of cancer and other diseases. Its products include TMX-101 for the treatment of localized bladder cancer, TMX-201 for the topical treatment of bladder cancer, skin cancer, and other indications, as well as for use as a vaccine adjuvant, and TMX-302 for use in preclinical trials for the treatment of autoimmune disease. The company was founded in October 2007 by Lorenzo Leoni, Roberto Maj, Rolf M. Zinkernagel and Dennis A. Carson and is headquartered in Lugano, Switzerland. | - |
Josef Hruska | M | - |
EffRx Pharmaceuticals SA
![]() EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | 1 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Schweiz | 15 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Alcide Barberis
- Persönliches Netzwerk